Counterpoint: Bispecific antibodies are becoming the preferred standard of care in relapsed/refractory multiple myeloma
Open Access
- 12 June 2026
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (19) , 6641-6644
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trialThe Lancet Oncology, 2026
- Retreatment With Anti-CD38-Based Combinations in Multiple Myeloma in Real-Life: Results From the Emmy Cohort StudyClinical Lymphoma Myeloma and Leukemia, 2025
- International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myelomaLeukemia, 2025
- Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myelomaBlood Cancer Journal, 2024
- Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panelBlood Cancer Journal, 2024
- Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed/refractory myeloma patients treated with teclistamab: Implications for outpatient step‐up dosingHemaSphere, 2024
- Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experienceBlood Cancer Journal, 2023
- Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysisJournal of Geriatric Oncology, 2023
- Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myelomaNature Medicine, 2023
- LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myelomaLeukemia, 2022